ICUS Weekly News Monitor 2-23-2017

  1. Dovepress, Feb 22, 2017, Diagnostic and prognostic values of contrast-enhanced ultrasound in breast cancer: a retrospective study Authors: Yi-Xuan Zhao
  2. ICUS - SAVE THE DATE!, First ICUS CEUS Educational Event - June 17, 2017

 


Dovepress

Diagnostic and prognostic values of contrast-enhanced ultrasound in breast cancer: a retrospective study

Feb 22, 2017
Authors: Yi-Xuan Zhao, Shuang Liu, Yan-Bing Hu, Yan-Yan Ge, Dong-Mei Lv

Department of Ultrasound, Second Hospital, Jilin University, Changchun, People’s Republic of China

Volume 2017:10 Pages 1123—1129

DOI: https://doi.org/10.2147/OTT.S124134

This study aimed to explore the diagnostic and prognostic values of contrast-enhanced ultrasound (CEUS) in breast cancer. Between September 2009 and October 2011, a total of 143 breast cancer patients and 161 healthy people were selected as case group and control group, respectively. After the identification of lesions by conventional ultrasound, all patients underwent CEUS. The CEUS images were analyzed, and time–intensity curves (TICs) were obtained. Hematoxylin–eosin and immunohistochemistry staining was performed on tissue specimens, according to which the expressions of estrogen receptor (ER), c-erb-B2, p53, and Ki-67 were measured. Multivariate logistic regression analysis was used to compare CEUS and TIC parameters between the two groups. Compared with the control group, cancer patients showed high enhancement, heterogeneous enhancement or defects in the central region, expansion of lesion diameter after enhancement and crab-like blur lesion edges. The peak intensity (PI), relative start time of enhancement, relative PI, and relative area under the curve in the case group were significantly higher than those in the control group. Logistic analysis showed that the uniformity of enhancement, expansion of lesion diameter, and relative PI were significant diagnostic parameters of breast cancer, with area under the curve being 0.798, 0.776, and 0.919, respectively. There were strong associations between CEUS characteristics and expressions of prognostic factors in breast cancer: the heterogeneous enhancement was common in c-erb-B2-positive tumors; the centripetal enhancement occurred more in ER-negative tumors; perforator vessels were often seen in tumors at high histological grade; perfusion defects were common in ER-negative, c-erb-B2-positive, and Ki-67-positive tumors. CEUS is a useful tool for the early diagnosis and prognosis of breast cancer.


ICUS SAVE THE DATE!

First ICUS CEUS Educational Event

Attend this exciting, one day ICUS educational event, providing information and instruction to novices in the field of CEUS.

Date: June 17, 2017
Location: Calgary AB, CANADA

Details and Registration Information to follow.

Get started on CEUS and learn about microbubble contrast agents, how they work, their safety, and their indications for liver and kidney mass characterization, and more.
Live CEUS demonstrations and hands on equipment exposure will include the latest from GE, Mindray, Philips, Samsung, Siemens and Toshiba.
And afterwards…..visit the beautiful Banff National Park, which has free entry for 2017 to celebrate Canada's 150th Anniversary!

ICUS Sponsors

ICUS gratefully acknowledges its 2017 sponsors:

dentons-logo2

silver-level

Toshiba Medical logo resized

samsung-logo

siemens-new-original

philips-icus-logo

mindray

Contact ICUS

  • Address: 1900 K Street, N.W.
    Washington, DC 20006-1102, USA
  • Telephone: 202-408-6199

About ICUS

ICUS is the world’s only professional society exclusively devoted to contrast-enhanced ultrasound (CEUS) medical imaging technology.

Learn more...

You are here: Home ICUS Weekly News Monitors ICUS Weekly News Monitor 2-23-2017